Global Multiple Sclerosis Therapeutics Market to Exceed $12.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Multiple Sclerosis market. The world market for multiple sclerosis therapeutics is projected to exceed $12.5 billion by the year 2015. With prevalence of the disease growing and presence of high-unmet need, demand for innovative and improved therapeutics to treat multiple sclerosis is increasing, presenting greater prospects for market growth.

Multiple Sclerosis Therapeutics: A Global Strategic Business Report

Multiple sclerosis is one of the most common autoimmune diseases. This chronic disease affects the central nervous system that includes the brain and the spinal cord. Each nerve fiber is protected by a tissue called myelin. In multiple sclerosis, the myelin gets damaged leading to formation of scar tissues, called sclerosis. The formation of several such scars is known as multiple sclerosis.

The United States dominates the world multiple sclerosis therapeutics market as stated by the new market research report on multiple sclerosis market. The United States is also the fastest growing geographic market for multiple sclerosis therapeutics, with growth led by high value disease modifying therapies used in the treatment of multiple sclerosis. Early diagnosis due to early intervention by primary care physicians is also a major factor contributing to the growth of the US multiple sclerosis market.

The multiple sclerosis therapeutics market is led by beta interferon drugs, encompassing Avonex, Rebif, and Betaseron. Other drugs in the market include Copaxone glatiramer acetate, and Tysabri. The existing therapies face major threat from oral pipeline therapies such as Sanofi-aventis' Teriflunomide, Active Biotech's Laquinimod, Merck's Cladribine and Novartis' FTY720. These pipeline candidates are expected to capture a significant share of the market, provided their efficacy is proven to be superior or comparable to currently available interferon and other therapies. MS pipeline also includes drugs with novel mechanisms of action such as GlaxoSmithKline's 683699, a VLA4 antagonist, that is expected to change market dynamics once approved.

Key market participants profiled in the report include Bayer Schering Pharma AG, Biogen Idec Inc., Elan Pharmaceuticals Inc., EMD Serono Inc., Genzyme Corp., Merck Serono SA, Novartis, Sanofi-Aventis SA, Teva Pharmaceuticals, among others.

The report titled "Multiple Sclerosis Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the multiple sclerosis market, key approved drugs, pipeline drugs, market dynamics, clinical trials, product introductions/ approvals, recent industry activity, and profiles of market participants. The study analyzes market data and analytics in terms of value sales for regions including The United States, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit -

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website